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REVIEW
Abstract: Anemia is a common complication of chronic kidney disease (CKD), with 
erythropoietin deﬁ  ciency being the major contributing factor. The availability of erythropoiesis-
stimulating agents (ESAs) has been a seminal advance in the treatment of anemia related to 
chronic kidney disease. Over the course of the last decade and a half, newer generations of 
ESAs have become available. The ﬁ  rst-generation ESAs or epoetins have a relatively shorter 
half-life and have traditionally been administered up to 3 times per week intravenously or 
subcutaneously to maintain adequate hemoglobin (Hb) levels. At the turn of the century, 
darbepoetin alfa, a hyperglycosylated form, became available for clinical use. It conferred greater 
metabolic stability in vivo owing to two additional N-linked carbohydrate chains attached to 
the protein backbone and has a half-life 3 times longer than that of epoetin (Macdougall et al 
1999). Recently developed and undergoing phase III clinical trials is the third-generation ESA, 
Continuous Erythropoiesis Receptor Activator (CERA), which has a methoxy-polyethylene 
glycol polymer chain integrated and has a longer elimination half-life than the ﬁ  rst- and second-
generation ESAs. Its receptor binding characteristics also differ from those of previous ESAs. 
Its major advantage is that extended dosing intervals are possible in the management of anemia 
related to erythropoietin deﬁ  ciency.
Keywords: CERA, epoetin, anemia, chronic kidney disease
Introduction
Anemia is common in chronic kidney disease (CKD) and although the cause is usually 
multifactorial, it is primarily related to the lack of erythropoietin (EPO) production. 
Mortality data from non-randomized studies show an association between anemia and 
risk of all-cause and cardiovascular death (Madore et al 1997; Locatelli et al 1998; Ma 
et al 1999; Xia et al 1999). However, randomized controlled trials targeting different 
hemoglobin (Hb) levels in hemodialysis patients with cardiac disease show conﬂ  icting 
results. Besarab et al (1998), in a study that was prematurely terminated, showed that 
in patients with pre-existing cardiac disease, treatment of anemia resulting in higher 
targeted Hb led to an increased risk of death. This study was prematurely halted prior 
to reaching the pre-speciﬁ  ed statistical stopping boundary. Normalization of Hb levels 
in incident hemodialysis patients does not have a beneﬁ  cial effect on cardiac structure 
(Parfrey et al 2005). Recent data suggest an association between high Hb levels and 
reduced mortality (Rayner et al 2004; Parfrey et al 2005). Trials in the pre-dialysis 
population are not powered to detect such a difference (Pollock and McMahon 2005). 
There is emerging evidence to suggest that the adverse effects of anemia are not only 
related to Hb levels but also to the low levels of EPO. EPO stimulates the proliferation 
and migration of endothelial cells, promotes angiogenesis (Anagnostou et al 1990; 
Yamaji et al 1996; Ribatti et al 1999, 2003) and prevents apoptotic injury (Kawakami 
et al 2001; Sekiguchi et al 2004). It is becoming evident that the beneﬁ  ts of EPO 
treatment may extend above and beyond the treatment of anemia.
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Anemia in renal failure and 
traditional treatment options
Prior to the availability of erythropoiesis-stimulating agents 
(ESAs), the treatment of anemia related to CKD was limited 
to recurrent blood transfusions. Transfusion dependence 
was associated with the risks of blood-borne infections, iron 
overload, and HLA sensitization, subsequently limiting renal 
transplantation opportunities. The development of ESAs has 
been a seminal advance in the treatment of anemia. This is 
coupled with the use of intravenous iron. The European Best 
Practice Guidelines (EBPG) (Locatelli et al 2004) suggest 
target Hb levels of >  11g/dL within 4 months of starting 
therapy. Although there is a lack of consensus surrounding 
the desired upper limit of the Hb level due to a lack of 
evidence, the EBPG suggest limiting Hb levels to <14 g/dL 
in hemodialysis patients and to <12  g/dL in patients with 
severe cardiovascular disease and in patients with diabetes 
and peripheral vascular disease. The CARI (Caring for 
Australians with Renal Impairment) Guidelines recommend 
Hb levels between 12 and 14 g/dL in those without proven or 
likely signiﬁ  cant cardiovascular disease and should not exceed 
12  g/dL in those with proven or signiﬁ  cant cardiovascular 
disease (Pollock and McMahon 2005). The main concerns 
with higher Hb targets include the risk of hypertension and 
vascular thrombosis. Iron deﬁ  ciency is common in patients 
with CKD and the cause is usually multifactorial. Once ESAs 
are commenced there is a rapid depletion of iron stores due to 
erythropoiesis. Failure to correct iron deﬁ  ciency commonly 
leads to EPO resistance. Iron is usually replaced parenterally 
and therapy is individualized based on the results of iron 
studies. Sufﬁ  cient iron should be administered to maintain 
a transferrin saturation of >20% and a minimum serum 
ferritin of >100 μg/L, although the majority would accept that 
ferritin should be maintained well above this level. This often 
involves ongoing regular doses of intravenous iron. 
EPO, a hematopoietic growth factor, was puriﬁ  ed from 
the urine of patients with aplastic anemia in 1977 (Miyake 
et al 1977), which led to the subsequent cloning of the 
human EPO gene in 1985 (Jacobs et al 1985) and the use 
of recombinant human EPO (Eschbach et al 1987). It is 
a sialoglycoprotein hormone that is immunologically and 
biologically indistinguishable from the endogenous form 
(Faulds and Sorkin 1989). The ﬁ  rst ESAs were recombinant 
human EPO alpha and beta (epoetins) which differed in their 
glycosylation. They were initially administered 2–3 times 
per week on the basis of their relatively short biological 
half-life (Halstenson et al 1991). However more recently it 
is recognized that the dosing interval may be extended to at 
least once per week (Barre et al 2004). Darbepoetin alfa, a 
second generation ESA, became available at the turn of the 
century. Due to its hyperglycosylated structure it has a longer 
elimination half-life (Macdougall et al 1999) allowing for an 
extended dosing interval. The latest ESA, a third-generation 
drug known as CERA (Continuous Erythropoietin Receptor 
Activator), has a higher molecular weight at 60 kDa and has 
a methoxy-polyethylene glycol chain integrated via amide 
bonds between the N-terminal amino group of lysine using a 
succinimidyl butanoic acid linker (Bailon et al 2003). It has 
a signiﬁ  cantly longer elimination half-life in vivo and allows 
for a further extension of dosing intervals.
Mechanism of action and 
pharmacokinetics
Receptor binding characteristics as well as the pharmacokinetics 
of CERA differ quite signiﬁ  cantly from ﬁ  rst and second 
generation ESAs (Macdougall et al 2003). CERA has a lower 
afﬁ  nity for its receptor and dissociates faster from the soluble 
EPO receptor compared with epoetin β, and has a reduced 
activity with respect to cellular proliferation in vitro. It is 
considered that the binding of CERA to its receptor is too 
brief to allow for internalization of the molecule therefore 
the repeated binding, stimulation and dissociation leads 
to prolonged activity in vivo and an extended elimination 
half-life. Pharmacokinetic properties have been studied in 
rodent and non-rodent models and the systemic clearance 
of CERA has been found to be much lower than that of 
epoetin, contributing to an extended elimination half-life and 
prolonged stimulation of erythropoiesis (Bailon et al 2003). 
The pharmacokinetic and pharmacodynamic proﬁ  le of CERA 
in anemic (Hb ≤12 g/dL) CKD patients on peritoneal dialysis 
have been examined in i.v. and s.c. dosing schedules. These 
studies demonstrated prolonged and comparable half-life 
for CERA (i.v. or s.c.), suggesting feasibility of extended 
dosing intervals in this population (Macdougall et al 2005). In 
healthy patients, the pharmacokinetic properties of s.c. CERA 
are unaffected by administration site (arm, abdomen, thigh) 
(Fishbane et al 2005), allowing for ﬂ  exibility in the injection 
site. An in vitro model showed that there was no effect of 
hemodialysis or hemoﬁ  ltration on serum concentrations of 
CERA (Dougherty et al 2003). 
Efﬁ  cacy and safety studies
Preclinical studies in vitro
The in vitro erythropoietic activity of CERA has been 
assessed by measuring its effect on the proliferation of a International Journal of Nanomedicine 2007:2(1) 35
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human acute myeloid leukaemia cell line (UT-7 cell line) 
that expresses the EPO receptor. Compared with epoetin, 
CERA stimulated less proliferation of UT-7 cells across a 
dose range 0.003–3 U/mL. However, in normocythemic mice, 
CERA induces greater reticulocytosis compared to epoetin 
β (Haselbeck et al 2002). This is possibly attributed to the 
binding characteristics and pharmacokinetics as described 
above. 
Preclinical studies in vivo
Preclinical studies in animal models using intravenous (i.v.) 
and subcutaneous (s.c.) CERA, in single and multiple doses, 
in the range 0.75–20 μg/kg demonstrate CERA to be a more 
potent stimulator of erythropoiesis than epoietin with respect 
to the magnitude and duration of response (Fishbane et al 
2003).
Phase I clinical studies in healthy 
volunteers
Phase I studies using single and multiple ascending doses 
via intravenous and subcutaneous routes resulted in 
dose-dependent increments of reticulocyte counts. In the 
randomized single ascending dose studies, healthy subjects 
received i.v. CERA in the dose range 0.4–3.2 μg/kg or s.c. 
CERA in the dose range 0.1–3.2 μg/kg vs placebo respectively 
(Reigner et al 2003). In the randomized multiple ascending 
dose studies, healthy subjects received 3 i.v. doses of CERA 
in the dose range 0.4–3.2 μg/kg every 3 weeks or 4 s.c. doses 
of CERA in the same dose range every fortnightly vs placebo, 
respectively. Peak effects in reticulocyte counts were seen at 
7 and 10 days after i.v. and s.c. administration respectively. 
Repeated dosing had no apparent clinically relevant effect 
on pharmacokinetics and accumulation did not occur with 3-
weekly i.v. dosing and was small with fortnightly s.c. dosing. 
CERA was generally well tolerated and no serious adverse 
events were reported (Dougherty et al 2004).
Phase II clinical studies in anemic 
patients 
The use of CERA for the treatment of anemia in CKD has 
been studied in Phase II clinical trials, both in ESA naïve 
dialysis and non-dialysis patients for the correction of anemia 
and the maintenance of Hb levels. de Francisco et al (de 
Francisco et al 2003) studied the efﬁ  cacy of s.c. CERA in 61 
dialysis patients (≥18 years; Hb 8–11 g/dL; on hemodialysis 
≥1 month and on peritoneal dialysis ≥2 months). Three dose 
levels were tested in sequence, with three dosing intervals in 
each sequence. Following a 4-week run-in period, patients 
in the ﬁ  rst sequence were randomized to receive CERA 
(0.15 μg/kg per week, 0.30 μg/kg per 2 weeks, or 0.45 μg/kg 
per 3 weeks). Patients in the second sequence received 
0.3 μg/kg per week and those in the third 0.45 μg/kg per week. 
After 6 weeks, dose adjustments were permitted according to 
deﬁ  ned Hb criteria and patients were followed for 12 weeks. 
A response was noted in all three dosing intervals and with all 
three starting doses. Mean increases in Hb were 0.84, 1.15, 
and 1.11  g/dL during the ﬁ  rst 6 weeks of constant dosing 
and 1.15, 2.50, and 2.35 g/dL during the entire study, in the 
low, intermediate, and high dose groups, respectively. Faster 
response time was associated with increasing dose with the 
median time to response in the low dose group of 52 days, 
in the intermediate dose group of 38 days, and in the high 
dose group of 30 days. No major adverse effects occurred. 
One patient experienced a pruritic rash. Hence this study 
showed CERA had a potent erythropoietic activity with a 
favorable safety proﬁ  le. Provenzano et al in the BA16528 
study examined the efﬁ  cacy of subcutaneous CERA in 65 
epoetin-naïve non-dialysis patients with CKD. After a 2 week 
run-in period, patients were randomized to receive CERA 
(0.15 μg/kg per week or 0.30 μg/kg per week or 0.60 μg/kg 
per week) once weekly, once every 2 weeks, or once every 3 
weeks. Patients were followed for 18 months. Hb increases 
occurred in each dose group with mean Hb increases of 0.31, 
0.70, and 1.76 g/dL during the ﬁ  rst 6 weeks in the 0.15, 0.30, 
and 0.60 μg/kg per week groups respectively. The Hb change 
from baseline was dose dependent but was independent of 
the frequency of administration and was sustained until the 
end of the study. The effect on Hb was independent of the 
frequency of administration and responses were sustained 
until the end of the study (Provenzano et al 2004). This 
extended to a long-term Phase II study over a 54-week period 
where patients continued to receive their original dose of 
s.c. CERA weekly, fortnightly, or once every 3 weeks with 
the aim of maintaining Hb levels at 11–12 g/dL. During this 
study period, mean Hb levels which were measured monthly 
were 11.3  g/dL with once weekly dosing, 11.4  g/dL with 
fortnightly dosing, and 11.7 g/dL with once every 3 weeks 
dosing. CERA was generally well tolerated. Hence CERA 
showed sustained and stable control of anemia in non dialysis 
patients with CKD.
Phase II studies have also been conducted in anemic 
dialysis patients to determine the efficacy of CERA in 
maintaining Hb levels (Hb 10–13  g/dL). In the ﬁ  rst study, 
patients on 3 times a week i.v. epoietin alfa (dose 80-250 IU/
kg per week) were changed to i.v. CERA. Three conversion International Journal of Nanomedicine 2007:2(1) 36
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factors were used to calculate dose, based on the estimated 
equi-effective dose of CERA to epoetin: 0.25 μg CERA/150 
IU epoetin, 0.4/150, and 0.6/150. Once weekly and once 
every 2 weeks administration schedules were assessed for 
each conversion factor and patients were followed for 19 
weeks. The results from the primary efﬁ  cacy analysis showed 
that the 0.6/150 conversion factor was adequate for providing 
stable Hb levels in patients treated once a fortnight. These 
studies showed that fortnightly i.v. CERA may maintain 
stable Hb levels in dialysis patients (Besarab et al 2004). 
In the second study by Locatelli et al 137 dialysis patients 
previously on s.c. epoetin (1–3 x/wk) were randomized to one 
of three arms receiving CERA, with the dose administered 
estimated to be equivalent to the previous epoetin dose and 
data from CERA exposure in healthy volunteers. The median 
CERA doses per week in each group were 19 μg/kg, 32 μg/kg, 
and 48 μg/kg. Once weekly, once every 3 weeks, and once 
every 4 weeks dosing schedules were assessed in each group 
and patients were followed for 19 weeks (21 weeks for once 
every 4 weeks cohorts) (Locatelli et al 2004). There was a 
dose-dependent effect on Hb change from baseline with 
mean Hb change of –0.63, –0.10, and 0.48 g/dL in each of 
the groups from lowest to highest doses respectively. This 
dose-ﬁ  nding study showed that s.c. CERA was effective in 
maintaining Hb levels in dialysis patients when administered 
every 4 weeks.
Clinical studies in cancer-related anemia
Limited studies to date have been undertaken assessing 
CERA in patients with cancer-related anemia. An exploratory 
Phase I–II dose escalation study was performed in patients 
with multiple myeloma and anemia (Hb ≤11g/dL). CERA 
was administered s.c. once every 3 weeks for 6 weeks 
with an optional extension to 12 weeks. Initially patients 
were randomized to receive doses of 2.0, 3.5, or 5.0 μg/kg. 
Following review of efﬁ  cacy and safety data, additional 
patients were assigned sequentially to doses of 6.5 and 
1.0  μg/kg, then 8.0 and 4.2  μg/kg. CERA (3.5–8.0  μg/kg) 
produced a dose-related increase in Hb of 1.6–2.3 g/dL. which 
resulted in a rapid and sustained Hb increase (Dmoszynska 
et al 2004).
Phase III clinical trials 
Four Phase III clinical trials for CERA were recently 
completed (Roche, data on ﬁ  le). In these maintenance studies, 
dialysis patients on stable maintenance treatment of anemia 
with epoietin or darbepoetin were randomized to either 
continue their treatment or to change over to CERA every 2 
weeks or 4 weeks. The primary endpoint was a change in Hb 
concentration between baseline and the evaluation period. 
These studies met their primary endpoints and showed that 
both routes of administration, ie, s.c. and i.v. at extended 
dosing intervals were effective in maintaining Hb levels. 
The ﬁ  rst study was designed to evaluate i.v. CERA (dosed 
every 2 weeks or every 4 weeks) for maintenance of Hb in 
dialysis patients previously on i.v. epoetin (dosed up to 3 
times weekly). The second study was similar to the ﬁ  rst, but 
CERA and epoietin were administered s.c. The third study 
was designed to evaluate i.v. CERA (dosed fortnightly) for 
maintenance of Hb in dialysis patients previously on i.v. 
darbepoetin alfa (dosed once a week or once a fortnight). 
The fourth study was designed to evaluate s.c. or i.v. 
CERA (dosed once a fortnight) in a pre-ﬁ  lled syringe in the 
maintenance of Hb in dialysis patients previously on epoetin 
(dosed up to 3 times weekly). The Phase III correction of 
anemia studies in dialysis and non-dialysis patients are 
nearing completion.
Safety proﬁ  le
CERA has been generally well tolerated with no unexpected 
safety concerns. In phase II studies in dialysis patients (n=109) 
administered i.v. or s.c. CERA for 12 months, the most 
common adverse events were hypotension (8.02%), muscle 
cramp (4.39%), hypertension (3.05%), headache (2.86%), 
and nasopharyngitis (2.10%). The most common serious 
adverse events were hypotension (5 events), myocardial 
infarction (5 events), cellulitis (4 events) and pancreatitis (4 
events). The frequency of the adverse events appeared to be 
characteristic of the patient population under study, rather 
than being attributable to CERA (Dougherty and Beyer 
2005b). In the Phase III trials the common adverse events 
in all treatment groups were infections, injuries, procedural 
complications, and gastrointestinal disorders. Again these 
events were characteristic of the population under study 
and not attributable to the study drug. There have been no 
reports of pure red cell aplasia with CERA as has occurred 
particularly with the ﬁ  rst-generation ESAs. However, this 
remains a potential or theoretical risk. In contrast to the 
side-effects reported with the ﬁ  rst- and second-generation 
ESAs, no changes in blood pressure were noted in dialysis 
patients after 12 months of treatment with i.v. or s.c. CERA 
(Dougherty and Beyer 2005a).
Patient implications
The greatest advantage of CERA over ﬁ  rst- and second-
generation ESAs is the extended dosing intervals needed International Journal of Nanomedicine 2007:2(1) 37
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to achieve adequate Hb levels for the treatment of anemia 
related to CKD and potentially cancer. This has an advantage 
not only for health care providers but also for patients, 
especially those who self-administer ESAs. For patients 
with anemia related to cancers, coinciding chemotherapy and 
other parenteral medications provides additional beneﬁ  ts. As 
the pharmacodynamics are unaffected by injection sites, this 
offers ﬂ  exibility and convenience to patients, suggesting that 
compliance would be increased. 
Conclusions
ESAs have revolutionized the treatment of anemia in CKD 
and cancers. Although there remains discussion around the 
mode of administration and the risk of pure red cell aplasia, 
the form of delivery of the ESA (preﬁ  lled syringe, single- or 
multi-use dispensers), difference in discomfort at the injection 
site, and so on, the main differentiating factor between the 
ESAs relates to their half-life and hence the dosing interval. 
First-generation ESAs have a relatively short half-life 
resulting in more frequent administration to maintain Hb 
levels. Darbepoetin, a second-generation ESA, has a longer 
elimination half life (Macdougall et al 2003) both in the 
i.v. and s.c. routes of administration. Darbepoetin is widely 
used and trials in CKD and dialysis patients have shown that 
initial one weekly dose is effective and safe (Macdougall et 
al 2003) both in the i.v. and s.c. routes of administration. 
Once-weekly darbepoetin alfa is equipotent to thrice-weekly 
epoetin (Nissenson et al 2002). Stable patients on once a week 
epoetin can be converted to once a fortnight darbepoetin alfa 
(Locatelli et al 2003; Brunkhorst et al 2004). Small studies 
have shown that monthly administration of darbepoetin was 
effective in the treatment of anemia in dialysis and non-
dialysis patients with CKD (Jadoul et al 2004; Ling et al 
2005; Theodoridis et al 2005). Hence darbopoetin alfa can 
be effectively and safely administered less frequently than 
epoetin. It is more potent at longer dosing intervals and at 
higher doses (Scott 2002). Initial data from clinical studies 
suggest that the pharmacokinetic and pharmacodynamic 
properties of CERA will allow a further increase in the dosing 
schedule of CERA. The clinical and economic consequences 
remain to be determined in large-scale clinical trials.
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